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Abstract
Background: Breast cancer is a complex, heterogene-
ous disease and one of the most common malignancies 
in women worldwide. The efficacy of chemotherapy as 
an important breast cancer treatment option has been 
severely limited because of the inherent or acquired re-
sistance of cancer cells. The molecular chaperone heat 
shock protein 90 (HSP90) upregulated in response to 
cellular stress is required for functions such as confor-
mational maturation, activation and stability in more 
than 200 client proteins, mostly of the signaling type. In 
this study, the expression of HSP90 isoforms including 
HSP90α and HSP90𝛽 in breast cancer cell lines before 
and after treatment with doxorubicin (DOX) was as-
sessed.
Material and Methods: The cell cytotoxicity of DOX in 
MDA-MB-231 and MCF-7 cell lines was determined 
using the MTT assay. Immunofluorescence and west-
ern blotting techniques were used to determine the 
expression of HSP90𝛽 in the cell lines before and after 
DOX treatment. Immunofluorescence was also con-
ducted to ascertain the expression of HSP90α.
Results: The MTT assay results showed that the MDA-
MB-231 cells (IC50=14.521 μМ) were more sensitive 
than the MCF-7 cells (IC50=16.3315 μМ) to DOX. The 
immunofluorescence results indicated that the ex-
pression of HSP90α in both cell lines decreased after 
exposure to DOX. The western blot and immunofluo-
rescence analyses showed that HSP90𝛽 expression de-
creased in the MCF-7 cells but increased in the MDA-
MB-231 cells after DOX treatment. Conclusion: The 
obtained results suggested that HSP90α and HSP90𝛽 
expression levels were reduced in the MCF-7 cells after 
exposure to DOX. In the MDA-MB-231 cells, HSP90α 
expression was reduced while HSP90𝛽 was found to be 
overexpressed following DOX treatment.
1. Introduction
Breast cancer is a complex and heterogeneous dis-
ease and one of the most common malignancies in 
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women worldwide. A total of 234,190 new breast cancer 
cases and 40,730 cancer deaths were anticipated to occur 
in the United States in 2015 [1, 2]. Such a high prevalence 
reflects the limited efficacy of chemotherapy, which can 
be primarily attributed to the development of resistance to 
chemotherapeutic drugs. Chemotherapeutic drugs such 
as doxorubicin (DOX) are generally used to treat a variety 
of malignancies such as breast cancer but the drug resist-
ance acquired by cancer cells can lead to treatment failure 
as surviving cancer cells become refractory to treatment 
and contribute to recurring and increased metastatic ac-
tivity [3-6]. There is currently an inadequate understand-
ing of the molecular and cellular mechanisms that govern 
breast cancer and the mechanisms underlying the chemo-
therapy resistance.
The heat shock proteins assist other proteins under 
normal and stress conditions to manage several actions 
including correct folding, assembly, intracellular locali-
zation, secretion, regulation and degradation [7]. Among 
these proteins, the molecular chaperone HSP90 with more 
than 200 target proteins has gained interest as a promising 
anti-cancer drug target, as many of these target proteins 
play an important role in disrupted pathways involved in 
different types of cancer [8]. Two highly elevated verte-
brate HSP90 isoforms, namely HSP90α and HSP90𝛽, are 
encoded by human genes [9, 10].
The breast cancer cell lines can be representative of the 
key genetic and transcriptional features involved in the 
breast tumors [11-14]. The pathobiology, screening and 
therapeutic features of the breast cancer can be examined 
using these cell lines [15, 16], which have several advan-
tages such as the relative ease of culturing, the possibility 
of being pharmacologically functional assays, and purity 
of cancerous cells or non-contaminated stromal cell [14].
The present study aimed to investigate two different 
breast cancer cell lines, MCF-7 and MDA-MB-231. MCF-
7 cells are estrogen receptor (ER)-positive cells that have 
been widely used to study estrogen-related pathways and 
the development of anti-hormonal therapies for breast 
cancer [17-19]. The MDA-MB231 cell line is ER-negative 
and resembles the recently characterized claudin-low 
tumor subtype of breast cancer [20, 21]. Additionally, the 
MCF-7 originates from metastatic sites in adenocarcino-
ma, as a tumorigenic adherent breast epithelial cell line, 
whereas the MDA-MB-231 cell line is a tumorigenic meta-
static breast cell line [22].
Studies are continuously conducted worldwide to identify 
the critical factors involved in cancer resistance to chemo-
therapy. To supplement existing efforts, the current study 
was carried out to compare the expression of HSP90α and 
HSP90𝛽 in MDA-MB-231 and MCF-7 cells after treatment 
with DOX.
2. Materials and Methods 
  Antibodies against HSP90𝛽 (sc-1057) and HSP90α (sc-
8262) and HRP secondary antibodies (sc-2354) and 
FITC-conjugated secondary antibodies (sc-2988) were 
obtained from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, Inc., Texas and Santa Cruz Biotechnol-
ogy, Inc., California, respectively). A beta actin antibody 
(ab8502) was obtained from United States Abcam. DOX 
(D1515) and MTT powder (M2128) were purchased from 
Germany Sigma.
2.1. Breast cancer cell lines 
  The MDA-MB-231 and MCF-7 cell lines (prepared from 
Pasture Institute of Iran) were initially cultured in RPMI 
1640 medium in the presence of 10% FBS and 100 U/ml of 
penicillin/streptomycin. The incubation was performed 
at 37°C with 5% CO2 and humidity.
2.2. MTT assay 
  A colorimetric assay with tetrazolium salt was used to as-
sess the anti-proliferative effects of DOX. The breast can-
cer cells were seeded at 10,000 cells/well in 96-well plates 
and allowed to grow for 48 h. The cells were then treated 
with different concentrations of DOX for 24 h, after which 
each well was poured by 10 μl of MTT [3-(4, 5-dimeth-
ylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide] and 5 
mg/ml in PBS (phosphate buffered saline) solution, and 
incubation was done at 37°C for 4 hours. After dissolving 
the formazan crystals in the DMSO, a microplate reader 
was used to read the absorbance of the wells at 570 nm. 
Finally, the data were reported as means ± standard devi-
ation for all experiments with more than three replicates, 
and statistically analyzed using SPSS software. The linear 
regression analysis was applied to estimate the half-max-
imal inhibitory concentrations (IC50) from the in vitro 
dose–response curves.
2.3. Western blotting 
  The MCF-7 and MDA-MB-231 cells were cultured in 100 
mm plates and treated with DOX (0, 0.2, 5 and 10 μM) for 
24 h. The cells were rinsed with cold PBS once and lysed 
with 500 μl of RIPA buffer (50 mM of Tris, pH=8, 150 mM 
of NaCl, 0.1% SDS, 0.5% Na deoxycholic acid, 1% NP-40 
or IGEPAL, 10 g/ml of aprotinin and 10 g/ml of leupep-
tin). A 25 G 5/8 needle was employed to break the cells 
whose extract was centrifuged for 30 min at 14,000 rpm at 
4˚C. Then, the resulting supernatant was stored at –20˚C 
until testing. Bradford method was followed to obtain the 
protein concentration. In addition, 24 μg proteins per well 
were electrophoresed using SDS polyacrylamide gels, 
and were then delivered onto a nitrocellulose membrane 
with a semi-dry gel transfer apparatus. Next, 5% milk in 
PBST (PBS with 0.05% Tween 20) was used to block the 
membranes at room temperature for 1-2 hours, and 
subsequently was incubated in the presence of a prima-
ry antibody against HSP90𝛽 or 𝛽-actin at 4˚C overnight. 
After that, the membranes were washed with PBST for 10 
min. The incubation was performed for an hour with the 
HRP-labeled secondary antibody in 5% milk in PBST. The 
washing was continued with PBST for 20-30 min, and then 
the membranes were treated with chemiluminescence re-
agents and exposed to Kodak film.
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2.4. Immunofluorescence 
   
 The study cell lines after culturing on coverslips within 
cell culture plates were treated at 0, 0.2, 5, 10 μM concen-
trations of DOX and incubated for 24 hours. In the next 
step, the cells following washing by PBS were fixed with 
4% paraformaldehyde/PBS at ambient temperature for 15 
min. The cells were rewashed and exposed to immuno-
fluorescence staining with a polyclonal primary antibody 
against HSP90𝛽 and HSP90𝛽 followed by the correspond-
ing FITC-conjugated secondary antibody. The stained 
cells were examined using a fluorescence microscope.
2.5. Statistical analysis
  The data obtained from the MTT assay were plotted. Also, 
linear charts were drawn; and the average, standard de-
viation, standard error, and IC50 values were calculated. 
Total Lab software was used for the densitometry of the 
bands. All values were presented as mean ± SEM from 
three independent experiments, and statistically signifi-
cant differences were determined among various groups 
by ANOVA and Tukey posttest using SPSS 12.0 statistical 
software.
3. Results
  The cytotoxic effects of DOX on the proliferation of the 
MCF-7 and MDA-MB-231 cell lines were evaluated by 
MTT assay. The IC50 of each cell line was calculated via lin-
ear regression. The results showed that the MDA-MB-231 
cells (IC50=14.521 μМ) were more sensitive than the MCF-7 
cells (IC50=16.3315 μМ) to 24 h DOX treatment.
  The expression of HSP90𝛽 before and after treatment 
with different concentrations of DOX was assayed us-
ing western blot analysis. The data from the western blot 
analysis showed that HSP90𝛽 expression decreased in 
the MCF-7 cells (5 and 10 μM DOX) but increased in the 
MDA-MB-231 cells (5 and 10 μM DOX) (Figures 1 and 2). 
The MCF-7 curve showed that HSP90𝛽 expression signif-
icantly decreased at a DOX concentration of 10 μM (P < 
0.01) (Figure 1-B). The MDA-MD-231 curve indicated that 
HSP90𝛽 expression significantly increased at DOX con-
centrations of 5 μМ (*P < 0.05) and 10 μМ (P < 0.01) (Figure 
2-B). The western blotting method was used to detect the 
HSP90𝛽 expression in the MCF-7 cells. Figure 2 (A) shows 
a sample of blots regarding three independent tests. The 
data, expressed in means ± standard deviation (n=3), in-
dicated that HSP90𝛽 expression significantly declined 
(P < 0.01) at a DOX concentration of 10 μM, as shown 
in (B). The representative immunofluorescence images 
(100X magnification) of the MCF-7 cells are presented 
in (C). Based on the the optical microscope, cell density 
decreased after exposure to DOX. Cytoplasmic ventricles 
and cellular attachments decreased was observed in the 
cells (D).
 The western blotting was applied to detect the HSP90𝛽 
expression in the MDA-MB-231 cells. Figure 2 (A) illus-
trates a sample of blots regarding three independent tests. 
The data, expressed as means ± standard deviation (n=3), 
revealed that the upper expression of HSP90𝛽 was signif-
icant at DOX concentrations of 5 μМ (P < 0.05) and 10 μМ 
(P < 0.01), as shown in (B). The representative immuno-
fluorescence images (100X magnification) of the MDA-
MB-231 cells are provided in (C). Based on the images 
seen from the optical microscope, cell density decreased 
after DOX exposure. Cytoplasmic ventricles and cellu-
lar attachments decreased as dosage increased, and cell 
death was observed in the cells (D).
 The immunofluorescence and western blot results 
showed that the MDA-MB-231 and MCF- 7 cells had differ-
ent levels of HSP90𝛽 expression in response to DOX treat-
ment. In the MCF-7 cells, HSP90𝛽 expression decreased 
Figure 2  These data show the expression of HSP90𝛽 before and 
after treatment with different concentrations of DOX (0, 0.2, 5, 
and 10 μM) in MDA-MB-231 cell line for 24 h. The expression of 
HSP90𝛽 in MDA-MB-231 cells was decreased in the concentra-
tion of 0.2 μM and increased in the concentrations of 5 and 10 μM 
and shows MDA-MB-231 cell density by optical microscope (x 
100).The scale bar represents 100 μm.
Figure 1  These data show the expression of HSP90𝛽 before and 
after treatment with different concentrations of DOX (0, 0.2, 5, 10 
μM) in MCF7 cell line for 24 h. The expression of HSP90𝛽 in MCF-
7 cells was increased in concentration of 0.2 μM and decreased 
in concentration of 5 and 10 μM and shows MCF7 cell density by 
optical microscope (x 100).The scale bar represents 100 μm.
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after DOX treatment. Although expression increased at a 
DOX concentration of 0.2 μM, the 10 μM dose of DOX sig-
nificantly reduced such expression. In the MDA-MB-231 
cells, HSP90α expression increased after DOX treatment. 
Expression decreased at a DOX concentration of 0.2 μM 
but significantly increased at DOX doses of 5 and 10 μM 
(Figures 1 and 2). The expression of HSP90𝛽 before and af-
ter exposure to DOX was determined via immunofluores-
cence. The findings revealed that HSP90α was expressed 
in the nucleus and cytoplasm before exposure to DOX but 
that expression decreased after both cell lines were ex-
posed to DOX. In the MDA-MB-231 cells, the expression 
of HSP90α decreased even further (Figure 3).
4. Discussion
  Breast cancer is a heterogeneous disease with several 
subtypes, whose current classification may be incom-
plete or unreliable given that patients with apparently 
identical types of breast cancer respond differently to the 
same treatment [2]. Chemotherapy resistance remains an 
unsolved clinical problem in cancer treatment. Studying 
different pathways involved in chemotherapy may ena-
ble an improved understanding of the mechanism that 
govern breast cancer and may shed light on more reliable 
biomarkers. In this research, the expression of HSP90𝛽 in 
MDA-MB-231 and MCF-7 cells before and after treatment 
with different concentrations of DOX was assayed. In this 
study, HSP90α protein expression was measured by the 
immunofluorescence technique in both cell lines before 
and after exposure to DOX. The toxicity of DOX against 
the two cell lines was compared using the MTT assay. 
The comparison of the IC50 values showed that the MDA-
MB-231 cells (14.521 μМ) were more sensitive than the 
MCF-7 cells (16.3315 μМ) to the treatment.
  The expression of HSP90α in both cell lines decreased 
after exposure to DOX. In the MCF-7 cells, DOX decreased 
the expression of HSP90𝛽 in a dose-dependent manner 
but in the MDA- MB-231 cells, HSP90𝛽 expression in-
creased after chemotherapy. In the MDA-MB-231 cells, 
HSP90𝛽 expression decreased with decreasing DOX dose 
but higher doses induced higher expression. Georgakis 
et al. tested the effect of an HSP90 inhibitor in anaplastic 
large cell lymphoma (ALCL) cells. Besides, they inhibited 
HSP90 without discerning the seemingly different roles 
of HSP90 isoforms [23]. However, the results of the cited 
study cannot be directly compared with the present re-
sults unless a specific HSP90 isoform inhibitor is used in 
breast cancer cell lines.
  Interestingly, different doses of a chemical sometimes 
induce opposite responses. For example, in immunoflu-
orescence and western blotting images of MDA-MB-231 
cells after exposure to 0.2 μM doxorubicin, the expression 
of HSP90𝛽 initially decreases but its expression increas-
es with increasing drug concentrations (Figure 2). Also, in 
MCF-7 cells after exposure to the concentration of 0.2 μM 
doxorubicin, the expression of HSP90𝛽 increased but its 
expression decreased as the concentration of the drug in-
creased (Figure 3). As observed in the MDA-MB-231 cells, 
a lower dose of DOX reduced HSP90𝛽 expression but a 
higher dose increased the expression. The most important 
insight derived from our results was that after chemother-
apy, HSP90𝛽 expression decreased in the MCF-7 cells but 
increased in the MDA- MB-231 cells. The reduced expres-
sion of HSP90𝛽 was expected in general after chemother-
apy but its increased expression in the MDA-MB-231 cells 
is interesting and should be investigated in more details in 
future studies. The HSP90 serves as a favorable therapeutic 
target in studying a wide range of cancers. In the early stag-
es of oncogenesis and the maintenance stage of malignant 
cell phenotypes, high HSP90 expression can be seen [24]. 
Hence, induction of apoptosis has been shown to be one of 
the leading approaches in anti-tumor therapy [25, 26].
  In a research, the therapeutic potential of sulforaphane 
(SFN), an antioxidant derived from broccoli, was evaluat-
ed against a chemoresistant cell line (BEAC) in vivo [27]. 
Immunodeficient mice were injected with BEAC cells, 
and after the appearance of palpable tumors, the mice 
were treated with SFN. The SFN induced cell apoptosis, 
suppressed the expression of multidrug resistance pro-
teins, and reduced tumor volume. The anticancer activity 
of SFN can induce caspase 8 and p21 and downregulates 
the HSP90 [28].
 In another research, the differential expression of HSP90α 
and HSP90𝛽 in other cancer cells were recorded. A north-
ern blot analysis showed that the levels of HSP90𝛽 and 
HSP90α mRNA in HL60 cells that are resistant to metho-
trexate or cisplatin were approximately two-to three-fold 
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Figure 3  The expression of HSP90α before and after exposure to 
Dox was measured. The expression of HSP90α was assessed be-
fore exposure to doxorubicin in the nucleus and cytoplasm but 
decreased after exposure to Dox in both cell lines. The scale bar 
represents 100 μm.
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higher than those in a drug-sensitive parental cell line [29]. 
In another work, the DOX- resistant colon cancer cell line 
LoVoDxR expressed a high level of HSP90𝛽constitutively 
but in a sensitive cell line, no constitutive expression of 
HSP90𝛽 was found [30]. An immunohistochemical study 
on colorectal cancer patients (26 men and 23 women) 
before chemotherapy showed the expression of HSP90α 
and HSP60 in the cytoplasm and the expression of HSP70 
in the nucleus of paracancerous tissue; the research also 
identified the expression of HSP60 and HSP70 in the cyto-
plasm and the expression of HSP90α in the nucleolus and 
extracellular matrix of cancerous tissue [31]. In another 
research, the mRNA expression of HSP60, HSP90α and 
HSP70 between precancerous and cancerous tissues was 
compared using RT-PCR. The results showed that HSP60, 
HSP70 and HSP90α mRNA levels were more highly ex-
pressed in cancerous tissue than in precancerous tissue. 
Western blot analysis confirmed the higher level of these 
three proteins in cancerous tissue [32, 33]. In another 
study, HSP90α protein was more highly expressed in can-
cerous tissue than in non- cancerous tissue [34]. Song et 
al. (2010) reported that the expression of HSP90 and PI-
3Ka-P110a was higher in the patients with ER/PR-posi-
tive and Her-2-negative breast cancer compared to the 
patients with ER/PR-negative or Her-2-positive breast 
cancer. The authors suggested HSP90 and PI3Ka-p110a as 
molecular prognostic markers for predicting early relapse 
in patients suffering from breast cancer [35].
  Cell line-specific factors may be part of the reason for 
the differences in results between the MDA-MB-231 and 
MCF-7 cells in the current study. MCF-7 cells express es-
trogen and progesterone receptors whereas MDA-MB-231 
cells do not express any of these receptors [19]. One of the 
major subtypes of breast cancer is that which expresses 
steroid hormone receptors [36]. Steroid hormone recep-
tors were found to be expressed in 65% and 80% of breast 
cancer patients before and after menopause, respective-
ly. This means that steroid hormone receptors are ex-
pressed, on average, in 75% of breast cancer patients [37]. 
In another study, the expression of Erk and pErk in MDA-
MB-231 and MCF-7 cells was compared after chemother-
apy with DOX or docetaxel. The results showed that the 
MDA-MB-231 and MCF- 7 cells responded in completely 
different ways to the same treatment. The expression of 
Erk and pErk in the MDA-MB-231 cells expression in the 
MCF-7 cells increased in a dose-dependent manner after 
chemotherapy. The expression of pErk decreased in the 
MDA-MB-231 cells but increased in the MCF-7 cells after 
docetaxel treatment [38].
  The HSP90 isoform-specific interaction with client proteins 
has also been reported in different studies. Co-immuno-
precipitation studies in two different systems showed that 
both isoforms interacted similarly with different co-chap-
erones in the HSP90 heterocomplex. Some of the substrates 
(CKIIB, c-Src, A-Raf and Erk) interacted similarly with both 
isoforms but after heat shock, they exhibited stronger inter-
action with HSP90α [39]. One of the HSP90𝛽 client proteins 
is the cellular inhibitor of apoptosis protein-1 (c-IAP1). In-
hibition of HSP90 proteins by small chemical molecules 
and the specific depletion of HSP90𝛽 by siRNA results in 
c-IAP1 auto- ubiquitination and degradation by the protea-
some machinery.
  The 𝛽 isoform accounts for the chaperone function of 
HSP90 toward c-IAP1 since the specific HSP90α depletion 
had no effect on the c-IAP1 percentage [40]. In a study by 
Dong et al. who investigated MDA-MB-231 breast cancer 
cell hypoxia in vivo, the inhibition of HSP90α by mono-
clonal antibody 1G6-D7 increased tumor cell death. They 
found that the expression of HSP90α secretion is an influ-
ential factor in the survival of hypoxic tumor cells [41]. In 
a study in the presence of B lymphocyte in inflammatory 
infiltration, estrogen and progesterone receptors disap-
peared, resulting in the accumulation of HSP90 in the cell 
and contributing to the stabilization of HER2/neu recep-
tors and the most prominent proteins that led to tumor 
progression [42].
 Overall, the studies discussed above have shown that 
HSP90 expression is important and the expression of 
HSP90𝛽 proceeds in a different manner in chemother-
apy-resistant cells.
5. Conclusion
  In this study, we observed decreased cellular density in 
both tested cell types after exposure to DOX. The expres-
sion of HSP90α in both cell lines was also decreased after 
exposure to DOX. The HSP90𝛽 expression was reduced 
in the MCF-7 cells but increased in the MDA-MB- 231 
cells after DOX treatment. These findings may be attrib-
uted to the greater sensitivity of the MDA-MB-231 cells to 
DOX than the MCF-7 cells or the absence of ERs in MDA-
MB-231 cells. Overall, the present results serve as prelim-
inary data for conducting future proof-of- concept studies 
to explore the role of HSP90 isoforms and estrogen recep-
tors in the sensitivity of breast cancer cells, cancer cell iso-
lates and xenografts to chemotherapeutic agents. Future 
studies are warranted to test the effect of overexpression 
of HSP90𝛽 on DOX sensitivity in MCF-7 cells, or the effect 
of knockout of HSP90𝛽 on the sensitivity of MDA-MB-231 
cells to DOX. Finally, it remains to be explored if HSP90𝛽
affects intracellular DOX accumulation in MDA-MB-231 
cells and through this potential mechanism regulates the 
sensitivity of cells to this drug.
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